Yuhan Q3 operating profit ₩34.7B, up 44%
Predicted impact: Low
Q3 operating profit up 44%, but the same results were already reported in the last 14 days.
Yuhan유한양행
000100 · KOSPI · ₩000100 · 유한양행
₩80,000▼ ₩1,700 (2.08%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −33.05%
- Market cap
- ₩5.9T
- Enterprise value
- ₩5.8T
- P/E
- 24.8×
- P/B
- 2.5×
- Dividend yield
- 0.8%
- ROE
- 9.9%
- Net margin
- 10.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−38.1% from the high
₩65,000Today: ₩79,700 – ₩81,800₩129,200
Returns
- 1W−7.2%
- 1M+8.0%
- 3M+13.2%
- 6M−14.6%
- YTD−28.8%
- 1Y−33.1%
- Volume today
- 196,144
- 0.7× the 20-day average
- Traded today
- ₩16B
- Listed shares
- 73,615,781
- EPS (12 months)
- ₩3,221
- Earnings yield 4.0%
AI research · Update noteYuhan Q3 2026 Preliminary Results: Operating Profit Up 44.2% but Down 43.4% From Q2The results are mixed.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Reported quarterly profit rose sharply year on year. Community: 0 bullish, 0 bearish posts this week.
- MomentumStrong6.5% over the last month; the price is above its 20-day average.
- News impactSome17 news items and filings in two weeks; 0 rated high impact, 4 medium.
- StreetSteady1 brokers, average target 38% from the price; last 30 days: 0 raised, 0 cut.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 27: buy ₩1.1B at the close (4.6% of 20-day average trading value)
On its 13 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 4.5% of trading value and pointed the same way 8 of 13 times.
- 2× KODEX Leverage ₩591M
- -2× KODEX 200 Futures Inverse 2X ₩280M
- -1× KODEX Inverse ₩101M
- 2× TIGER Leverage ₩36M
- 2× TIGER 200IT Leverage ₩35M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 32 funds.
- KODEX 2000.1%
- TIGER 2000.1%
- KODEX 200TR0.1%
- KODEX Leverage2×0.1%
- RISE 2000.1%
- KIWOOM 200TR0.1%
- ACE 2000.1%
- PLUS 2000.1%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 80,200
Basis +0.25% · implied rate +5.7%
Open interest 152,920 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Yuhan stock overview
Yuhan (유한양행, KRX: 000100) is listed on KOSPI, in the Biotech & Pharma sector. Yuhan Corporation manufactures and sells pharmaceuticals, chemical and industrial products, veterinary drugs, and household goods. Its shares closed at ₩80,000 on Oct 27, 2026, down 2.08% on the day, giving it a market value of ₩5.9T.
Key facts
- Market cap
- ₩5.9T
- Sector
- Biotech & Pharma
- Latest price change
- −2.08%
- As of
- Oct 27, 2026
- Main business
- Yuhan Corporation manufactures and sells pharmaceuticals, chemical and industrial products, veterinary drugs, and household goods.
Quick answers about Yuhan
- What does Yuhan do?
- Yuhan Corporation manufactures and sells pharmaceuticals, chemical and industrial products, veterinary drugs, and household goods. Its main products include Lazertinib (Lazcluze), Antiflamin, Bicom C, Duowell, Kofsyrup, and Elena. The company also has a health care division selling household products such as Yuhan Lox bleach, and an overseas business that exports products and supplies active pharmaceutical ingredients through its subsidiary Yuhan Chemical.
- What is the market cap of Yuhan?
- The market capitalisation of Yuhan was ₩5.9T at the close on Oct 27, 2026.
- What is the analyst target price for Yuhan?
- The average target price of 1 broker covering Yuhan is ₩110,000 (range ₩110,000 to ₩110,000), 37.5% above versus the latest price, based on each broker's latest public report within six months.
- Who are the largest shareholders of Yuhan?
- According to the latest official filings, the largest reported holders are National Pension Service (6.83%, as of Mar 3, 2026); BlackRockFundAdvisors (6.50%, as of Aug 10, 2026); GK Asset (5.03%, as of May 11, 2026).
- When is the next earnings report from Yuhan?
- Korean companies rarely announce results dates in advance. Based on when Yuhan filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Yuhan?
- Yes. The National Pension Service held 6.83% of Yuhan shares as of Mar 3, 2026.
Company profile
Yuhan Corporation manufactures and sells pharmaceuticals, chemical and industrial products, veterinary drugs, and household goods. Its main products include Lazertinib (Lazcluze), Antiflamin, Bicom C, Duowell, Kofsyrup, and Elena. The company also has a health care division selling household products such as Yuhan Lox bleach, and an overseas business that exports products and supplies active pharmaceutical ingredients through its subsidiary Yuhan Chemical.
Written by AI from the company's latest annual report.
- Korean name
- 유한양행
- Sector
- Biotech & Pharma
- CEO
- 대표이사 조욱제
- Founded
- Jun 1926
- Listed
- Nov 1962
- Listed shares
- 73,615,781
- Fiscal year ends
- Month 12
- Website
- www.yuhan.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
- SK Bioscience302440 · ₩2.5T₩31,750−0.78%
Recent news
Yuhan 3Q operating profit of ₩33.2B, up 50.8% year on year
Predicted impact: Medium
Q3 operating profit up 50.8%; preliminary earnings already disclosed in the last 14 days.
Yuhan's Willow House wins Presidential Award at 2026 Korea Space Culture Awards
Predicted impact: Low
Design award for a space; no financial relevance.
Recent filings
See all- Preliminary earningsOct 28, 2026
- Investor relations (IR) eventOct 27, 2026
- Insider shareholding reportOct 2, 2026
- Major sales or supply contractSep 15, 2026
- Insider shareholding reportSep 9, 2026
Titles in Korean until English translations are added.
Also known as: Yuhan / 유한양행 / 000100 / KRX:000100
Source: KRX statistical information